Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$7.71 - $11.56 $740 - $1,109
96 Added 45.71%
306 $3,000
Q2 2023

Jul 28, 2023

SELL
$7.14 - $9.29 $1,435 - $1,867
-201 Reduced 48.91%
210 $1,000
Q1 2023

May 10, 2023

SELL
$6.65 - $10.69 $824 - $1,325
-124 Reduced 23.18%
411 $3,000
Q4 2022

Feb 10, 2023

SELL
$5.96 - $8.53 $1,621 - $2,320
-272 Reduced 33.71%
535 $4,000
Q3 2022

Nov 08, 2022

SELL
$5.95 - $14.3 $4,646 - $11,168
-781 Reduced 49.18%
807 $5,000
Q2 2022

Aug 05, 2022

BUY
$10.6 - $13.28 $5,363 - $6,719
506 Added 46.77%
1,588 $19,000
Q1 2022

May 13, 2022

BUY
$10.37 - $12.73 $4,583 - $5,626
442 Added 69.06%
1,082 $13,000
Q4 2021

Feb 11, 2022

SELL
$10.21 - $15.27 $20 - $30
-2 Reduced 0.31%
640 $7,000
Q3 2021

Nov 10, 2021

SELL
$14.07 - $17.3 $3,376 - $4,152
-240 Reduced 27.21%
642 $9,000
Q2 2021

Aug 11, 2021

SELL
$16.62 - $18.94 $1,047 - $1,193
-63 Reduced 6.67%
882 $15,000
Q1 2021

May 13, 2021

SELL
$15.15 - $19.78 $2,651 - $3,461
-175 Reduced 15.63%
945 $16,000
Q4 2020

Feb 12, 2021

SELL
$16.86 - $19.67 $286 - $334
-17 Reduced 1.5%
1,120 $21,000
Q3 2020

Nov 13, 2020

SELL
$15.4 - $20.16 $415 - $544
-27 Reduced 2.32%
1,137 $20,000
Q2 2020

Aug 13, 2020

BUY
$18.24 - $21.45 $2,061 - $2,423
113 Added 10.75%
1,164 $21,000
Q1 2020

May 15, 2020

SELL
$16.28 - $25.63 $48 - $76
-3 Reduced 0.28%
1,051 $21,000
Q4 2019

Feb 14, 2020

SELL
$19.57 - $23.52 $1,056 - $1,270
-54 Reduced 4.87%
1,054 $25,000
Q3 2019

Nov 13, 2019

SELL
$19.85 - $22.76 $297 - $341
-15 Reduced 1.34%
1,108 $22,000
Q2 2019

Jul 09, 2019

SELL
$17.59 - $21.1 $1,213 - $1,455
-69 Reduced 5.79%
1,123 $24,000
Q1 2019

May 10, 2019

BUY
$18.01 - $20.11 $21,467 - $23,971
1,192 New
1,192 $24,000

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.33B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Zions Bancorporation, N.A. Portfolio

Follow Zions Bancorporation, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zions Bancorporation, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Zions Bancorporation, N.A. with notifications on news.